{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=7&state=Wisconsin", "query": { "state": "Wisconsin", "city": "Milwaukee", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 5340, "total_pages": 534, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=8&state=Wisconsin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=6&state=Wisconsin&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T22:07:29.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00795639", "title": "Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension", "Pulmonary Hypertension" ], "interventions": [ { "name": "Sitaxsentan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 183, "start_date": "2008-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2015-03-24", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 32, "location_summary": "Fountain Valley, California • Mather, California • Sacramento, California + 28 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Mather", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795639" }, { "nct_id": "NCT02785939", "title": "Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "CCND1 Gene Amplification", "CCND2 Gene Amplification", "CCND3 Gene Amplification", "CDK4 Gene Amplification", "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2014-09", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 1065, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785939" }, { "nct_id": "NCT01143402", "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 32, "location_summary": "Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143402" }, { "nct_id": "NCT00799773", "title": "Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thrombotic Thrombocytopenic Purpura" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Plasma exchange", "type": "PROCEDURE" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Carelon Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3, "start_date": "2009-04", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799773" }, { "nct_id": "NCT04394351", "title": "Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "11 Years", "sex": "ALL", "summary": "1 Year to 11 Years" }, "enrollment_count": 102, "start_date": "2020-09-01", "completion_date": "2024-05-14", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04394351" }, { "nct_id": "NCT04635059", "title": "Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2021-06-01", "completion_date": "2024-10-27", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04635059" }, { "nct_id": "NCT02728388", "title": "Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NEUROFIBROMATOSIS 1" ], "interventions": [ { "name": "aminolevulinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Donald Basel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "14 Years to 30 Years" }, "enrollment_count": 30, "start_date": "2016-09-16", "completion_date": "2026-03-28", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728388" }, { "nct_id": "NCT02661451", "title": "Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortic Valve Stenosis" ], "interventions": [ { "name": "SAPIEN 3 THV", "type": "DEVICE" }, { "name": "Optimal Heart Failure Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "DEVICE", "BIOLOGICAL" ], "sponsor": "Cardiovascular Research Foundation, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2016-09", "completion_date": "2025-02", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 46, "location_summary": "Chandler, Arizona • La Jolla, California • Los Angeles, California + 37 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02661451" }, { "nct_id": "NCT00644605", "title": "A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension, Pulmonary" ], "interventions": [ { "name": "sildenafil", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2002-10", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 24, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00644605" }, { "nct_id": "NCT00335153", "title": "Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Parkinson's Disease" ], "interventions": [ { "name": "Levodopa-carbidopa intestinal gel", "type": "DRUG" }, { "name": "CADD-Legacy® 1400 ambulatory infusion pump", "type": "DEVICE" }, { "name": "PEG tube", "type": "DEVICE" }, { "name": "J-tube", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 354, "start_date": "2008-01", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2015-01-16", "last_synced_at": "2026-10-17T22:07:29.578Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335153" } ] }